Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81


NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells.

Odqvist L, Sánchez-Beato M, Montes-Moreno S, Martín-Sánchez E, Pajares R, Sánchez-Verde L, Ortiz-Romero PL, Rodriguez J, Rodríguez-Pinilla SM, Iniesta-Martínez F, Solera-Arroyo JC, Ramos-Asensio R, Flores T, Palanca JM, Bragado FG, Franjo PD, Piris MA.

Clin Cancer Res. 2013 May 1;19(9):2319-30. doi: 10.1158/1078-0432.CCR-12-3151. Epub 2013 Mar 27.


Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells.

Saitoh Y, Martínez Bruyn VJ, Uota S, Hasegawa A, Yamamoto N, Imoto I, Inazawa J, Yamaoka S.

Lung Cancer. 2010 Dec;70(3):263-70. doi: 10.1016/j.lungcan.2010.03.001. Epub 2010 Mar 24.


Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells.

Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y, Matsubara K, Qi X, Saitoh T, Imoto I, Inazawa J, Utsunomiya A, Watanabe T, Masuda T, Yamamoto N, Yamaoka S.

Blood. 2008 May 15;111(10):5118-29. doi: 10.1182/blood-2007-09-110635. Epub 2008 Feb 27.


Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.

Yamamoto M, Ito T, Shimizu T, Ishida T, Semba K, Watanabe S, Yamaguchi N, Inoue J.

Cancer Sci. 2010 Nov;101(11):2391-7. doi: 10.1111/j.1349-7006.2010.01685.x. Epub 2010 Aug 24.


The kinase NIK as a therapeutic target in multiple myeloma.

Gardam S, Beyaert R.

Expert Opin Ther Targets. 2011 Feb;15(2):207-18. doi: 10.1517/14728222.2011.548861. Epub 2011 Jan 5. Review.


Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells.

McPherson AJ, Snell LM, Mak TW, Watts TH.

J Biol Chem. 2012 Jun 29;287(27):23010-9. doi: 10.1074/jbc.M112.350538. Epub 2012 May 8.


Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation.

Liao G, Zhang M, Harhaj EW, Sun SC.

J Biol Chem. 2004 Jun 18;279(25):26243-50. Epub 2004 Apr 14.


NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway.

Thu YM, Su Y, Yang J, Splittgerber R, Na S, Boyd A, Mosse C, Simons C, Richmond A.

Oncogene. 2012 May 17;31(20):2580-92. doi: 10.1038/onc.2011.427. Epub 2011 Oct 3.


Protective effect of Ginkgolids (A+B) is associated with inhibition of NIK/IKK/IkappaB/NF-kappaB signaling pathway in a rat model of permanent focal cerebral ischemia.

Wang X, Qin ZH, Shi H, Savitz SI, Qin AP, Jiang Y, Zhang HL.

Brain Res. 2008 Oct 9;1234:8-15. doi: 10.1016/j.brainres.2008.07.102. Epub 2008 Aug 5.


NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells.

Nishina T, Yamaguchi N, Gohda J, Semba K, Inoue J.

Biochem Biophys Res Commun. 2009 Oct 9;388(1):96-101. doi: 10.1016/j.bbrc.2009.07.125. Epub 2009 Jul 29.


Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F.

Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.


Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.


Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers.

Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, Yamaguchi K, Uchimaru K, Ogawa S, Watanabe T.

Cancer Cell. 2012 Jan 17;21(1):121-35. doi: 10.1016/j.ccr.2011.12.015.


TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.

Kanno Y, Sakurai D, Hase H, Kojima H, Kobata T.

J Recept Signal Transduct Res. 2010 Apr;30(2):121-32. doi: 10.3109/10799891003634509.


TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma).

Nuñez C, Cansino JR, Bethencourt F, Pérez-Utrilla M, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M.

Histopathology. 2008 Aug;53(2):166-76. doi: 10.1111/j.1365-2559.2008.03092.x.


Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways.

Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO.

Eur J Pharmacol. 2006 Aug 7;542(1-3):1-7. Epub 2006 May 6.


MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK).

Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X.

Oncogene. 2012 Aug 2;31(31):3607-20. doi: 10.1038/onc.2011.523. Epub 2011 Nov 21.


Supplemental Content

Support Center